170 related articles for article (PubMed ID: 23041832)
1. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Joseph NM; Phillips J; Dahiya S; M Felicella M; Tihan T; Brat DJ; Perry A
Mod Pathol; 2013 Mar; 26(3):315-26. PubMed ID: 23041832
[TBL] [Abstract][Full Text] [Related]
2. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY
Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165
[TBL] [Abstract][Full Text] [Related]
4. Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma.
Barrows BD; Rutkowski MJ; Gültekın SH; Parsa AT; Tıhan T
Turk Patoloji Derg; 2012; 28(2):95-103. PubMed ID: 22627626
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
6. [Morphological classification of glioblastomas].
Figarella-Branger D; Bouvier C; Moroch J; Michalak S; F Burel-Vandenbos
Neurochirurgie; 2010 Dec; 56(6):459-63. PubMed ID: 20864138
[TBL] [Abstract][Full Text] [Related]
7. Genetic profile of astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
Brain Tumor Pathol; 2011 Jul; 28(3):177-83. PubMed ID: 21442241
[TBL] [Abstract][Full Text] [Related]
8. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic alterations in glioblastomas with oligodendroglial component.
Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
[TBL] [Abstract][Full Text] [Related]
10. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas.
Ohnishi A; Sawa H; Tsuda M; Sawamura Y; Itoh T; Iwasaki Y; Nagashima K
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1052-9. PubMed ID: 14575240
[TBL] [Abstract][Full Text] [Related]
11. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
12. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
[TBL] [Abstract][Full Text] [Related]
13. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
[TBL] [Abstract][Full Text] [Related]
14. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
15. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
Rhee W; Ray S; Yokoo H; Hoane ME; Lee CC; Mikheev AM; Horner PJ; Rostomily RC
Glia; 2009 Apr; 57(5):510-23. PubMed ID: 18837053
[TBL] [Abstract][Full Text] [Related]
17. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.
Mokhtari K; Paris S; Aguirre-Cruz L; Privat N; Crinière E; Marie Y; Hauw JJ; Kujas M; Rowitch D; Hoang-Xuan K; Delattre JY; Sanson M
Neuropathol Appl Neurobiol; 2005 Feb; 31(1):62-9. PubMed ID: 15634232
[TBL] [Abstract][Full Text] [Related]
18. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors.
Aguirre-Cruz L; Mokhtari K; Hoang-Xuan K; Marie Y; Criniere E; Taillibert S; Lopes M; Delattre JY; Sanson M
J Neurooncol; 2004 May; 67(3):265-71. PubMed ID: 15164981
[TBL] [Abstract][Full Text] [Related]
20. [Oligodendroglial and neuronal component in glioblastomas: possible relation with prognosis].
Pinto LW; Chimelli L
Arq Neuropsiquiatr; 2004 Dec; 62(4):1074-8. PubMed ID: 15608972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
